COMPANY OVERVIEW

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole.

---

LOCATION

Berkeley, CA, USA

---

THERAPEUTIC AREAS

---

WEBSITE

https://cariboubio.com/

---

CAREER WEBSITE

https://cariboubio.com/careers

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Jul 27, 2021

Caribou Biosciences Announces Closing of Upsized Initial Public Offering

Jul 22, 2021

Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

Jul 12, 2021

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Jun 22, 2021

Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors

May 17, 2021

Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board

For More Press Releases

---